Literature DB >> 30327937

Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM).

A Santaballa1,2, J De Castro3,4, J Maurel5,4, M Lázaro6,4, R Vera7,4, E Alba8,4.   

Abstract

PURPOSE: To determine the current management of oral and intravenous chemotherapy (OC and IVC) in outpatient clinics of Oncology Departments in Spain to detect opportunities for improvement.
MATERIALS AND METHODS: The Spanish Society of Medical Oncology designed a questionnaire specifically for Heads of Oncology Department: 142 were invited and 52 responded.
RESULTS: In most centers, the waiting time (69.7%) and time at the outpatient clinic (84.8%) was shorter for patients receiving OC compared to those receiving IVC. The time spent at the outpatient clinic by the patients having OC was approximately 30 min (88.5%). In addition, the time expended by the oncologist with each patient was shorter when they were treated with OC in 21.2% of cases.
CONCLUSIONS: Patients' waiting times and individual dedication of oncologists might be reduced by administering OC, and general management might be improved. This should be considered when planning therapies if OC is an option.

Entities:  

Keywords:  Intravenous chemotherapy; Oral chemotherapy; Outpatient clinic; Survey

Mesh:

Substances:

Year:  2018        PMID: 30327937     DOI: 10.1007/s12094-018-1951-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  11 in total

Review 1.  Concordance in cancer medication management.

Authors:  Betty Chewning; Joseph B Wiederholt
Journal:  Patient Educ Couns       Date:  2003-05

2.  Medication therapy management: 10 years of experience in a large integrated health care system.

Authors:  Djenane Ramalho de Oliveira; Amanda R Brummel; David B Miller
Journal:  J Manag Care Pharm       Date:  2010-04

3.  Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.

Authors:  Maria Rosa Strada; Raffaella Palumbo; Antonio Bernardo; Alberto Riccardi; Cristina Teragni; Guido Poggi; Mara Frascaroli; Alessio Amatu; Benedetta Montagna; Federico Sottotetti; Barbara Tagliaferri; Giovanni Bernardo
Journal:  Clin Breast Cancer       Date:  2011-12-06       Impact factor: 3.225

4.  Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system.

Authors:  K Le Lay; E Myon; S Hill; L Riou-Franca; D Scott; M Sidhu; D Dunlop; R Launois
Journal:  Eur J Health Econ       Date:  2007-02-28

5.  Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.

Authors:  Siu-Fun Wong; Mark Bounthavong; Cham P Nguyen; Timothy Chen
Journal:  J Natl Compr Canc Netw       Date:  2016-03       Impact factor: 11.908

6.  Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC.

Authors:  Lars Henrik Jensen; Kell Osterlind; Carsten Rytter
Journal:  Lung Cancer       Date:  2008-03-26       Impact factor: 5.705

Review 7.  Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG).

Authors:  L Biganzoli; S Lichtman; J-P Michel; D Papamichael; E Quoix; C Walko; M Aapro
Journal:  Eur J Cancer       Date:  2015-09-01       Impact factor: 9.162

8.  Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous.

Authors:  Sandro Barni; Beata Freier; Isabel Garau; Jean-Loup Mouysset; Marcela Sediva; Claudio Zamagni; Gilles Berdeaux; Cecilia de Almeida Agudo
Journal:  Curr Med Res Opin       Date:  2016-07-22       Impact factor: 2.580

9.  Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study.

Authors:  Florian Strasser; Catherine Sweeney; Jie Willey; Susanne Benisch-Tolley; J Lynn Palmer; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2004-06       Impact factor: 3.612

10.  Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities.

Authors:  Barry V Fortner; Kurt Tauer; Ling Zhu; Theodore A Okon; Kelley Moore; Davis Templeton; Lee Schwartzberg
Journal:  BMC Cancer       Date:  2004-05-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.